BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tan HK, James PD, Sniderman KW, Wong F. Long-term clinical outcome of patients with cirrhosis and refractory ascites treated with transjugular intrahepatic portosystemic shunt insertion. J Gastroenterol Hepatol. 2015;30:389-395. [PMID: 25168607 DOI: 10.1111/jgh.12725] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 Armbruster M, Wirth S, Seidensticker M. [Interventional radiology as emergency therapy]. Radiologe 2020;60:258-68. [PMID: 31970424 DOI: 10.1007/s00117-019-00637-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Tzschätzsch H, Sack I, Marticorena Garcia SR, Ipek-ugay S, Braun J, Hamm B, Althoff CE. Time-Harmonic Elastography of the Liver is Sensitive to Intrahepatic Pressure Gradient and Liver Decompression after Transjugular Intrahepatic Portosystemic Shunt (TIPS) Implantation. Ultrasound in Medicine & Biology 2017;43:595-600. [DOI: 10.1016/j.ultrasmedbio.2016.10.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
3 Will V, Rodrigues SG, Stirnimann G, Gottardi A, Bosch J, Berzigotti A. Transjugular intrahepatic portosystemic shunt and alfapump® system for refractory ascites in liver cirrhosis: Outcomes and complications. United European Gastroenterol J 2020;8:961-9. [PMID: 32588789 DOI: 10.1177/2050640620938525] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Gallo A, Dedionigi C, Civitelli C, Panzeri A, Corradi C, Squizzato A. Optimal Management of Cirrhotic Ascites: A Review for Internal Medicine Physicians. J Transl Int Med 2020;8:220-36. [PMID: 33511049 DOI: 10.2478/jtim-2020-0035] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Tejedor-Tejada J, Fuentes-Valenzuela E, García-Pajares F, Nájera-Muñoz R, Almohalla-Álvarez C, Sánchez-Martín F, Calero-Aguilar H, Villacastín-Ruiz E, Pintado-Garrido R, Sánchez-Antolín G. Long-term clinical outcome and survival predictors in patients with cirrhosis after 10-mm-covered transjugular intrahepatic portosystemic shunt. Gastroenterol Hepatol 2021;44:620-7. [PMID: 33249114 DOI: 10.1016/j.gastrohep.2020.10.018] [Reference Citation Analysis]
6 Suraweera D, Jimenez M, Viramontes M, Jamal N, Grotts J, Elashoff D, Lee EW, Saab S. Age-related Morbidity and Mortality After Transjugular Intrahepatic Portosystemic Shunts. Journal of Clinical Gastroenterology 2017;51:360-3. [DOI: 10.1097/mcg.0000000000000541] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
7 Rajesh S, George T, Philips CA, Ahamed R, Kumbar S, Mohan N, Mohanan M, Augustine P. Transjugular intrahepatic portosystemic shunt in cirrhosis: An exhaustive critical update. World J Gastroenterol 2020; 26(37): 5561-5596 [PMID: 33088154 DOI: 10.3748/wjg.v26.i37.5561] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Adlakha N, Russo MW. Outcomes After Transjugular Intrahepatic Portosystemic Shunt in Cirrhotic Patients 70 Years and Older. J Clin Med. 2020;9. [PMID: 32023959 DOI: 10.3390/jcm9020381] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Fortune B, Cardenas A. Ascites, refractory ascites and hyponatremia in cirrhosis. Gastroenterol Rep (Oxf). 2017;5:104-112. [PMID: 28533908 DOI: 10.1093/gastro/gox010] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
10 Artru F, Moschouri E, Denys A. Direct intrahepatic portocaval shunt (DIPS) or transjugular transcaval intrahepatic portosystemic shunt (TTIPS) to treat complications of portal hypertension: indications, technique, and outcomes beyond Budd-Chiari syndrome. Clin Res Hepatol Gastroenterol 2022;:101858. [PMID: 34999250 DOI: 10.1016/j.clinre.2022.101858] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
11 Neong SF, Adebayo D, Wong F. An update on the pathogenesis and clinical management of cirrhosis with refractory ascites. Expert Rev Gastroenterol Hepatol 2019;13:293-305. [PMID: 30791777 DOI: 10.1080/17474124.2018.1555469] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
12 Aithal GP, Palaniyappan N, China L, Härmälä S, Macken L, Ryan JM, Wilkes EA, Moore K, Leithead JA, Hayes PC, O'Brien AJ, Verma S. Guidelines on the management of ascites in cirrhosis. Gut 2021;70:9-29. [PMID: 33067334 DOI: 10.1136/gutjnl-2020-321790] [Cited by in Crossref: 47] [Cited by in F6Publishing: 30] [Article Influence: 47.0] [Reference Citation Analysis]
13 Wang HL, Lu WJ, Zhang YL, Nie CH, Zhou TY, Zhou GH, Zhu TY, Wang BQ, Chen SQ, Yu ZN, Jing L, Sun JH. Comparison of Transjugular Intrahepatic Portosystemic Shunt in the Treatment of Cirrhosis With or Without Portal Vein Thrombosis: A Retrospective Study. Front Med (Lausanne) 2021;8:737984. [PMID: 34671621 DOI: 10.3389/fmed.2021.737984] [Reference Citation Analysis]
14 Zhao D, Zhang G, Wang M, Zhang C, Li J. Portal pressure gradient and serum albumin: A simple combined parameter associated with the appearance of ascites in decompensated cirrhosis treated with transjugular intrahepatic portosystemic shunt. Clin Mol Hepatol 2019;25:210-7. [PMID: 30897897 DOI: 10.3350/cmh.2018.0083] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
15 Will V, Rodrigues SG, Berzigotti A. Current treatment options of refractory ascites in liver cirrhosis - A systematic review and meta-analysis. Dig Liver Dis 2022:S1590-8658(21)00894-X. [PMID: 35016859 DOI: 10.1016/j.dld.2021.12.007] [Reference Citation Analysis]
16 European Association for the Study of the Liver. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406-460. [PMID: 29653741 DOI: 10.1016/j.jhep.2018.03.024] [Cited by in Crossref: 660] [Cited by in F6Publishing: 520] [Article Influence: 165.0] [Reference Citation Analysis]
17 Adebayo D, Neong SF, Wong F. Ascites and Hepatorenal Syndrome. Clin Liver Dis 2019;23:659-82. [PMID: 31563217 DOI: 10.1016/j.cld.2019.06.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Stirnimann G, Berg T, Spahr L, Zeuzem S, McPherson S, Lammert F, Storni F, Banz V, Babatz J, Vargas V, Geier A, Stallmach A, Engelmann C, Trepte C, Capel J, De Gottardi A. Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis. Aliment Pharmacol Ther. 2017;46:981-991. [PMID: 28940225 DOI: 10.1111/apt.14331] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
19 Iwakiri Y, Trebicka J. Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy. JHEP Rep 2021;3:100316. [PMID: 34337369 DOI: 10.1016/j.jhepr.2021.100316] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Hung ML, Lee EW. Role of Transjugular Intrahepatic Portosystemic Shunt in the Management of Portal Hypertension. Clinics in Liver Disease 2019;23:737-54. [DOI: 10.1016/j.cld.2019.07.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
21 Chen Y, Qiu H, Zhang X. Transjugular intrahepatic portal shunt in the treatment of portal hypertension due to cirrhosis: single center experience. BMC Surg 2019;19:191. [PMID: 31830972 DOI: 10.1186/s12893-019-0659-5] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
22 Tripathi D, Stanley AJ, Hayes PC, Travis S, Armstrong MJ, Tsochatzis EA, Rowe IA, Roslund N, Ireland H, Lomax M, Leithead JA, Mehrzad H, Aspinall RJ, McDonagh J, Patch D. Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension. Gut 2020;69:1173-92. [PMID: 32114503 DOI: 10.1136/gutjnl-2019-320221] [Cited by in Crossref: 62] [Cited by in F6Publishing: 43] [Article Influence: 31.0] [Reference Citation Analysis]
23 Wong F, Bendel E, Sniderman K, Frederick T, Haskal ZJ, Sanyal A, Asrani SK, Capel J, Kamath PS. Improvement in Quality of Life and Decrease in Large-Volume Paracentesis Requirements With the Automated Low-Flow Ascites Pump. Liver Transpl 2020;26:651-61. [PMID: 31999044 DOI: 10.1002/lt.25724] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
24 Wan YM, Li YH, Xu ZY, Wu HM, Wu XN, Xu Y, Guo T. Transjugular Intrahepatic Portosystemic Shunt:The Impact of Portal Venous Pressure Declines on Shunt Patency and Clinical Efficacy. Acad Radiol 2019;26:188-95. [PMID: 29934023 DOI: 10.1016/j.acra.2018.05.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
25 Tahara T, Mori K, Mochizuki M, Ishiyama R, Noda M, Hoshi H, Lefor AK, Shinozaki S. Tolvaptan is effective in treating patients with refractory ascites due to cirrhosis. Biomed Rep 2017;7:558-62. [PMID: 29250327 DOI: 10.3892/br.2017.1005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
26 Trebicka J. Emergency TIPS in a Child-Pugh B patient: When does the window of opportunity open and close? J Hepatol. 2017;66:442-450. [PMID: 27984174 DOI: 10.1016/j.jhep.2016.10.025] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 8.0] [Reference Citation Analysis]
27 Adebayo D, Neong SF, Wong F. Refractory ascites in liver cirrhosis. Am J Gastroenterol. 2018;. [PMID: 29973706 DOI: 10.1038/s41395-018-0185-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
28 Yao X, Zhou H, Huang S, Tang SH, Qin JP. Effects of transjugular intrahepatic portosystemic shunt using the Viatorr stent on hepatic reserve function in patients with cirrhosis. World J Clin Cases 2021; 9(7): 1532-1542 [PMID: 33728297 DOI: 10.12998/wjcc.v9.i7.1532] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
29 Jeyanesan D, Balachandrakumar VK, Hogan B. Guideline review: transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension—a BSG guideline. Frontline Gastroenterol. [DOI: 10.1136/flgastro-2022-102151] [Reference Citation Analysis]
30 Dhaliwal A, Armstrong MJ, Tripathi D. Patient Selection for Transjugular Intrahepatic Portosystemic Stent Shunt (TIPSS) Insertion in Variceal Bleeding and Refractory Ascites. Curr Hepatology Rep 2017;16:241-9. [DOI: 10.1007/s11901-017-0361-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
31 Büttner L, Aigner A, Pick L, Brittinger J, Steib CJ, Böning G, Streitparth F. 25 years of experience with transjugular intrahepatic portosystemic shunt (TIPS): changes in patient selection and procedural aspects. Insights Imaging 2022;13:73. [PMID: 35416547 DOI: 10.1186/s13244-022-01216-5] [Reference Citation Analysis]
32 Manekeller S, Kalff JC. [Esophageal variceal bleeding: management and tips on transjugular intrahepatic portosystemic shunt]. Chirurg 2019;90:614-20. [PMID: 30963209 DOI: 10.1007/s00104-019-0949-6] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Biggins SW, Angeli P, Garcia-Tsao G, Ginès P, Ling SC, Nadim MK, Wong F, Kim WR. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021;74:1014-48. [PMID: 33942342 DOI: 10.1002/hep.31884] [Cited by in Crossref: 46] [Cited by in F6Publishing: 29] [Article Influence: 46.0] [Reference Citation Analysis]
34 Ponzo P, Campion D, Rizzo M, Roma M, Caviglia GP, Giovo I, Rizzi F, Bonetto S, Saracco GM, Alessandria C. Transjugular intrahepatic porto-systemic shunt in cirrhotic patients with hepatorenal syndrome - chronic kidney disease: Impact on renal function. Digestive and Liver Disease 2021. [DOI: 10.1016/j.dld.2021.09.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Buechter M, Manka P, Gerken G, Canbay A, Blomeyer S, Wetter A, Altenbernd J, Kahraman A, Theysohn JM. Transjugular Intrahepatic Portosystemic Shunt in Patients with Portal Hypertension: Patency Depends on Coverage and Interventionalist's Experience. Dig Dis 2018;36:218-27. [PMID: 29316565 DOI: 10.1159/000486030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
36 Torner M, Mangal A, Scharnagl H, Jansen C, Praktiknjo M, Queck A, Gu W, Schierwagen R, Lehmann J, Uschner FE, Graf C, Strassburg CP, Fernandez J, Stojakovic T, Woitas R, Trebicka J. Sex specificity of kidney markers to assess prognosis in cirrhotic patients with TIPS. Liver Int 2020;40:186-93. [PMID: 31448496 DOI: 10.1111/liv.14230] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
37 Fonio P, Discalzi A, Calandri M, Doriguzzi Breatta A, Bergamasco L, Martini S, Ottobrelli A, Righi D, Gandini G. Incidence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (TIPS) according to its severity and temporal grading classification. Radiol Med. 2017;122:713-721. [PMID: 28510807 DOI: 10.1007/s11547-017-0770-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
38 Parbhu SK, Adler DG. Endoscopic management of acute esophageal variceal bleeding. Techniques in Gastrointestinal Endoscopy 2017;19:74-8. [DOI: 10.1016/j.tgie.2017.03.002] [Reference Citation Analysis]
39 Teng D, Zuo H, Liu L, Dong J, Ding L. Long-term clinical outcomes in patients with viral hepatitis related liver cirrhosis after transjugular intrahepatic portosystemic shunt treatment. Virol J. 2018;15:151. [PMID: 30285813 DOI: 10.1186/s12985-018-1067-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
40 Garcia-Pagan JC, Francoz C, Montagnese S, Senzolo M, Mookerjee RP. Management of the major complications of cirrhosis: Beyond guidelines. J Hepatol 2021;75 Suppl 1:S135-46. [PMID: 34039484 DOI: 10.1016/j.jhep.2021.01.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
41 Triantafyllou T, Aggarwal P, Gupta E, Svetanoff WJ, Bhirud DP, Singhal S. Polytetrafluoroethylene-Covered Stent Graft Versus Bare Stent in Transjugular Intrahepatic Portosystemic Shunt: Systematic Review and Meta-Analysis. J Laparoendosc Adv Surg Tech A 2018;28:867-79. [PMID: 29356589 DOI: 10.1089/lap.2017.0560] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
42 Wan YM, Li YH, Xu Y, Wu HM, Li YC, Wu XN, Yang JH. Predictors of Shunt Dysfunction and Overall Survival in Patients with Variceal Bleeding Treated with Transjugular Portosystemic Shunt Creation Using the Fluency Stent Graft. Acad Radiol 2018;25:925-34. [PMID: 29373208 DOI: 10.1016/j.acra.2017.11.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
43 Stockhoff L, Schultalbers M, Tergast TL, Hinrichs JB, Gerbel S, Meine TC, Manns MP, Simon N, Cornberg M, Meyer BC, Maasoumy B. Safety and feasibility of transjugular intrahepatic portosystemic shunt in elderly patients with liver cirrhosis and refractory ascites. PLoS One 2020;15:e0235199. [PMID: 32584874 DOI: 10.1371/journal.pone.0235199] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]